Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 14, 2014

Intrexon Acquires Codexis’ Hungarian Lab Operations

  • Intrexon acquired laboratory operations in Budapest, Hungary, from Codexis, which develops biocatalysts for the pharmaceutical and complex chemistry industries. According to Intrexon officials, the deal expands the company’s strain and protein development capabilities, as well as strengthen fermentation process optimization and scaleup. 

    “Intrexon’s Industrial Products Division (IPD) will absorb the Budapest lab staff of experienced scientific professionals. Integration of the Budapest team and their expertise with Intrexon’s suite of synthetic biology technologies and capabilities will allow Intrexon to better serve current collaborators and to attract new opportunities for active pharmaceutical ingredients (API) and industrial and consumer product collaborations,” said Robert F. Walsh, president of the IPD.

    Earlier this week Intrexon signed an agreement with generic drug manufacturer Amneal Pharmaceuticals to develop an improved production process for a complex API. The companies say they will continue to explore other similar opportunities for collaboration in the future.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »